Vigeo Therapeutics, Inc.
Novel cancer therapeutics based on proprietary biology platforms
- Sector
- Biotech
- Headquarters
- Cambridge, MA
- Founded
- 2011
- Latest Form D
- $7.5M, Mar 2021
- Total capital
- $17.6M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $17.6M
- 3 Form D · last Mar 2021
- 67 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 3 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$7.5M
- Private capital raisedForm D · SEC · 2nd filing$7.6M
- Private capital raisedForm D · SEC · 1st filing$2.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- James E. MahoneyDirectorNamed in SEC Form D filings
- Jason DingesDirectorNamed in SEC Form D filings
- Jing WatnickExecutive Officer, DirectorNamed in SEC Form D filings
- Peter B. FinnExecutive OfficerNamed in SEC Form D filings
- Stephanie E. O'BrienDirectorNamed in SEC Form D filings
- Westerly E. Nolin, Ph.D.DirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 3- PendingMethods And Compositions For The Treatment Of CancerUSPTOApplication 18717178
- PendingMethods And Compositions For The Treatment Of CancerUSPTOApplication PCTUS2022045154
- PendingMethods for Diagnosis and TreatmentUSPTOApplication 63290834
Related companies, and why
- Mytos, Inc.Similar federal contract value in Biotech · null in contracts
- CollPlant Biotechnologies LtdSimilar federal contract value in Biotech · null in contracts
- Xenetic Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- SPLIT BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- Frame Technology, Inc.Similar federal contract value in Biotech · null in contracts
- Autonomy Bio Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .